Artiva Biotherapeutics, Inc. (ARTV) AI Stock Analysis

• Market Cap: $76.99M
• Dividend Yield: N/A
• Average Volume (3M): 116.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 89
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -2.94
• Shares Outstanding: 24,363,120
• 10 Day Avg. Volume: 178,462
• 30 Day Avg. Volume: 116,550
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 229.97
• Price to Cash Flow (P/CF): -2.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $20.25
• Price Target Upside: 540.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Artiva Biotherapeutics, Inc. displays potential through revenue growth and improved equity. However, significant challenges remain in achieving profitability and generating positive cash flow, as evidenced by negative margins and substantial net losses. The technical indicators reflect a bearish trend, and the valuation is hampered by a negative P/E ratio. The stock's near-term outlook is challenging, pending improvements in operational efficiency and financial performance.

Positive Factors

Clinical Efficacy

Artiva reported impressive data of AlloNK + rituximab with a 62% complete response rate in CAR-T naive patients with aggressive NHL.

Manufacturing and Cost Efficiency

The company’s manufacturing process facilitates low costs, consistent products, and scalability, allowing production of AlloNK for an estimated COGS of less than $6,000 per patient.

Regulatory Designation

AlloNK has received FDA Fast Track designation for the treatment of lupus nephritis in combination with Rituxan or Gazyva.

Negative Factors

Development Plans

Artiva does not currently plan to continue development for AlloNK + rituximab in NHL.

Strategic Focus

The company is not pursuing oncology at this time due to costs and commercial considerations.

Artiva Biotherapeutics, Inc. Business Overview & Revenue Model

Company Description

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

How the Company Makes Money

Artiva Biotherapeutics generates revenue primarily through the development and commercialization of its NK cell therapy products. The company may earn income from licensing agreements, collaborations, and partnerships with pharmaceutical and biotech companies seeking to incorporate Artiva's NK cell technology into their own therapeutic portfolios. Additionally, Artiva may receive milestone payments and royalties based on the successful development and commercialization of its therapies. The company's business model relies on advancing its therapies through clinical trials to achieve regulatory approval, ultimately leading to market access and sales revenue. Significant partnerships with other industry leaders can also contribute to its financial performance by providing funding, resources, and commercial opportunities.

Artiva Biotherapeutics, Inc. Financial Statement Overview

Summary

Artiva Biotherapeutics, Inc. is experiencing revenue growth and improvements in equity, yet continues to face profitability and cash flow challenges. The company demonstrates potential in its revenue trajectory, but operational inefficiencies and reliance on external financing pose significant risks. Future performance will depend on the ability to achieve profitability and improve cash flow generation.

Income Statement

Artiva Biotherapeutics, Inc. has demonstrated significant revenue growth from $2,002,000 in 2021 to $251,000 in 2024, indicating a positive trajectory. However, the company is still facing substantial net losses, with a net profit margin of -232.9% in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows improvement in stockholders' equity, moving from negative to positive in 2024, but the company still has a high debt-to-equity ratio due to previous negative equity. The equity ratio improved to 89.1% in 2024, showing enhanced financial stability despite previous challenges.

Cash Flow

Cash flow analysis indicates difficulties in generating positive free cash flow, with a free cash flow of -$55.7 million in 2024. The operating cash flow to net income ratio is negative, pointing to challenges in converting earnings to cash. There is a growth in financing cash flow, reflecting reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
251.00K	33.49M	4.93M	2.00M	0.00
	Gross Profit
251.00K	33.49M	4.93M	2.00M	0.00
	EBIT
-67.28M	-30.67M	-59.83M	-53.27M	-18.27M
	EBITDA
-64.85M	-28.41M	-58.67M	-71.58M	-17.72M
	Net Income Common Stockholders
-58.49M	-27.70M	-58.39M	-71.83M	-17.99M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
185.43M	76.97M	102.53M	160.92M	25.44M
	Total Assets
209.58M	105.11M	133.05M	169.93M	29.23M
	Total Debt
14.35M	16.91M	19.45M	1.74M	2.12M
	Net Debt
-25.88M	-36.59M	-83.08M	-159.18M	-23.33M
	Total Liabilities
22.94M	267.13M	273.75M	258.78M	50.80M
	Stockholders Equity
186.64M	-162.01M	-140.70M	-88.86M	-21.57M
Cash Flow		Free Cash Flow
-55.67M	-50.69M	-57.13M	-17.03M	-13.82M
	Operating Cash Flow
-55.03M	-47.43M	-50.83M	-15.30M	-13.54M
	Investing Cash Flow
-120.46M	-25.98M	-6.30M	-1.72M	-284.00K
	Financing Cash Flow
162.23M	24.39M	-1.26M	152.75M	37.40M

Artiva Biotherapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GILD	75 Outperform	$139.22B	292.26	2.28%	2.75%	6.16%	-91.54%
Sector *	49 Neutral	$6.85B	0.81	-52.91%	2.50%	17.48%	1.17%
IOVA	48 Neutral	$1.17B	―	-57.48%	―	13698.99%	31.46%
ADAP	46 Neutral	$52.72M	―	-273.36%	―	194.23%	45.50%
NKTX	43 Neutral	$141.92M	―	-31.94%	―	―	30.76%
FATE	42 Neutral	$97.33M	―	-54.21%	―	-78.55%	-0.92%
ARTV	35 Underperform	$76.99M	―		―	―	―